Citations

Clear

1325 citation(s) found for "Mayo, Angela".

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma
Tandon, Nidhi , Sidana, Surbhi , Lacy, Martha Q. , Kapoor, Prashant , Kourelis, Taxiarchis , Warsame, Rahma , Dingli, David , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L. , Kyle, Robert A. , Lust, John A., Russell, Stephen J. , Kumar, Shaji , Russell, Stephen J , Sidana, Surbhi , Dingli, David , Rajkumar, S. Vincent , Gertz, Morie A. , Buadi, Francis K. , Gonsalves, Wilson I. , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S.

Mayo Clinic

Blood Advances | March 1, 2019 | Volume: 3 | Issue: 5 | Pages: 744-750

10.1182/bloodadvances.2018022806 | PMID 30824418 Get It

Abstract We evaluated the impact of achieving a rapid response in 840 newly diagnosed multiple myeloma patients from 2004 to 2015. Rates of very good partial response (VGPR) or better were 29% (240/840) after 2 cycles of treatment, 42% (350/840) after 4 cycles of treatment, and 66% (552/840) as best response. Early responders after 2 cycles of treatment had higher rates of light chain disease, anemia, renal failure, International Staging System (ISS) stage III disease, and high-risk cytogenetics, especially t(4;14), and were more likely to have received triplet therapy and undergo transplant. Median progression-free survival (PFS) and overall survival (OS) were not different among patients with ≥VGPR and <VGPR after 2 cycles (PFS, 28 vs 30 months, P = .6; OS, 78 vs 96 months, P = .1) and 4 cycles (PFS, 31 vs 29 months; OS, 89 vs 91 months, P = .9), although both were improved, with ≥VGPR as best response (PFS, 33 vs 22 months, P < .001; OS, 102 vs 77 months, P = .003). On multivariate analysis stratified by transplant status, achievement of ≥VGPR after 2 cycles was not associated with improved PFS (hazard ratio [95% confidence interval]; transplant cohort, 1.1 [0.7-1.6]; nontransplant cohort, 1.2 [0.8-1.7]) or OS (transplant cohort, 1.6 [0.9-2.9]; nontransplant cohort, 1.5 [1.0-2.4]). Covariates in the model included high-risk cytogenetics, ISS stage III, triplet therapy, creatinine ≥2 mg/dL, light chain disease, and age. Although patients with high-risk disease are more likely to achieve early response, a rapid achievement of a deep response by itself does not affect long-term outcomes.
Substratification of patients with newly diagnosed standard‐risk multiple myeloma
Binder, Moritz , Lacy, Martha Q. , Hayman, Suzanne R. , Hwa, Yi L. , Zeldenrust, Steven R., Lust, John A., Russell, Stephen J. , Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Gonsalves, Wilson , Kumar, Shaji K , Binder, Moritz , Russell, Stephen J , Rajkumar, S. Vincent , Ketterling, Rhett P. , Dispenzieri, Angela , Gertz, Morie A. , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I.

Mayo Clinic

British Journal of Haematology | February 15, 2019 | Volume: 185 | Issue: 2 | Pages: 254-260

10.1111/bjh.15800 | PMID 30768679 Get It

SummaryDespite the absence of high‐risk cytogenetics and lower International Staging System (ISS) stages, a subset of patients with multiple myeloma (MM) experience poor overall survival (OS). We studied 1461 patients with newly diagnosed MM to identify patient and disease characteristics that predict a high‐risk phenotype among standard‐risk patients. Fifty‐six percent of all patients presented with standard‐risk disease. Among them, advanced age, extremes of body mass index, non‐hyperdiploid karyotype and abnormal lymphocyte counts were associated with worse OS. Standard‐risk patients with 0–1 of these adverse factors (hazard ratio [HR] 0·32, 95% confidence interval [CI] 0·24–0·43, P < 0·001) and 2 adverse factors (HR 0·54, 95% CI 0·41–0·72, P < 0·001) experienced better OS than high‐risk patients. Two or more adverse factors were present in 17% of standard‐risk patients and were associated with OS comparable to high‐risk patients (HR 0·91, 95% CI 0·67–1·24, P = 0·548). Predictive power among standard‐risk patients was improved using score groups compared to ISS stages. Patients with standard‐risk MM are a heterogeneous group with one in six patients experiencing OS comparable to high‐risk disease. Patients at risk can be identified using readily available patient and disease characteristics. These findings emphasize the importance of accurate risk stratification and help explain part of the heterogeneity observed in clinical practice.
Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma
Sidana, Surbhi , Jevremović, Dragan , Tandon, Nidhi , Greipp, Patricia T. , Gertz, Morie A. , Rajkumar, S. Vincent , Kumar, Shaji , Tandon, Nidhi , Gertz, Morie A , Rajkumar, S Vincent , Jevremovic, Dragan , Sidana, Surbhi , Greipp, Patricia T , Ketterling, Rhett P. , Baughn, Linda B. , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | January 25, 2019 | Volume: 94 | Issue: 5 | Pages: No page available

10.1002/ajh.25420 | PMID 30680770 Get It

Teaching Video NeuroImages: MT-TL1 mutation presenting as chronic progressive external ophthalmoplegia
Parsons, Angela, Mehta, Shyamal H. , Acierno, Marie D, Dhamija, Radhika , Parsons, Angela M, Dhamija, Radhika

Mayo Clinic

Neurology | January 22, 2019 | Volume: 92 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000006817 | PMID 30665919 Get It

Interactive reflective writing-enhanced reflection and professional identity formation in medical education – in reply to (1) Hichem Bouayed, Samiullah Dost, and Tanzeel Hussian and (2) Alexander Morgan, James Moore and Alexander Duff
Wald, Hedy S. , Anthony, David, White, Jordan , Reis, Shmuel , Esquibel, Angela Y., Esquibel, Angela

Mayo Clinic

Medical Teacher | January 20, 2019 | Volume: 41 | Issue: 2 | Pages: 236-237

10.1080/0142159x.2018.1543861 | PMID 30663478 Get It

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis
Solomon, Scott D. , Adams, David , Kristen, Arnt V. , Grogan, Martha , Maurer, Mathew S. , Merlini, Giampaolo , Slama, Michel , Brannagan, Thomas H., Shah, Amil M. , Garg, Pushkal, Vaishnaw, Akshay, Karsten, Verena, Gollob, Jared , Vest, John, Merlini, Giampaolo , Brannagan, T H , Adams, David , Shah, Amil , Solomon, Scott David , González-Duarte, Alejandra , Maurer, Mathew S , Damy, Thibaud , Dispenzieri, Angela , Berk, John L. , Chen, Jihong , Vest, John, Suhr, Ole B.

Mayo Clinic

Circulation | January 17, 2019 | Volume: 139 | Issue: 4 | Pages: 431-443

10.1161/circulationaha.118.035831 | PMID 30586695 Get It

Background: Hereditary transthyretin-mediated (hATTR) amyloidosis is a rapidly progressive, multisystem disease that presents with cardiomyopathy or polyneuropathy. The APOLLO study assessed the efficacy and tolerability of patisiran in patients with hATTR amyloidosis. The effects of patisiran on cardiac structure and function in a prespecified subpopulation of patients with evidence of cardiac amyloid involvement at baseline were assessed. Methods: APOLLO was an international, randomized, double-blind, placebo-controlled phase 3 trial in patients with hATTR amyloidosis. Patients were randomized 2:1 to receive 0.3 mg/kg patisiran or placebo via intravenous infusion once every 3 weeks for 18 months. The prespecified cardiac subpopulation comprised patients with a baseline left ventricular wall thickness ≥13 mm and no history of hypertension or aortic valve disease. Prespecified exploratory cardiac end points included mean left ventricular wall thickness, global longitudinal strain, and N -terminal prohormone of brain natriuretic peptide. Cardiac parameters in the overall APOLLO patient population were also evaluated. A composite end point of cardiac hospitalizations and all-cause mortality was assessed in a post hoc analysis. Results: In the cardiac subpopulation (n=126; 56% of total population), patisiran reduced mean left ventricular wall thickness (least-squares mean difference ± SEM: –0.9±0.4 mm, P =0.017), interventricular septal wall thickness, posterior wall thickness, and relative wall thickness at month 18 compared with placebo. Patisiran also led to increased end-diastolic volume (8.3±3.9 mL, P =0.036), decreased global longitudinal strain (–1.4±0.6%, P =0.015), and increased cardiac output (0.38±0.19 L/min, P =0.044) compared with placebo at month 18. Patisiran lowered N -terminal prohormone of brain natriuretic peptide at 9 and 18 months (at 18 months, ratio of fold-change patisiran/placebo 0.45, P <0.001). A consistent effect on N -terminal prohormone of brain natriuretic peptide at 18 months was observed in the overall APOLLO patient population (n=225). Median follow-up duration was 18.7 months. The exposure-adjusted rates of cardiac hospitalizations and all-cause death were 18.7 and 10.1 per 100 patient-years in the placebo and patisiran groups, respectively (Andersen–Gill hazard ratio, 0.54; 95% CI, 0.28–1.01). Conclusions: Patisiran decreased mean left ventricular wall thickness, global longitudinal strain, N -terminal prohormone of brain natriuretic peptide, and adverse cardiac outcomes compared with placebo at month 18, suggesting that patisiran may halt or reverse the progression of the cardiac manifestations of hATTR amyloidosis. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01960348.
EEG in WNV Neuroinvasive Disease
Parsons, Angela, Grill, Marie , Feyissa, Anteneh M. , Hocker, Sara E. , Crepeau, Amy Z. , Parsons, Angela M, Grill, Marie F, Crepeau, Amy, Feyissa, A M , Britton, Jeffrey W.

Mayo Clinic

Journal of Clinical Neurophysiology | January 15, 2019 | Volume: 36 | Issue: 2 | Pages: 135-140

10.1097/wnp.0000000000000558 | PMID 30648977 Get It

Purpose: Neuroinvasive West Nile virus (WNV) is rare, occurring in less than 1% of those infected, and may manifest as meningitis, encephalitis, and/or acute flaccid paralysis. Patients may present initially with nonspecific symptoms including fevers. Although rare, neuroinvasive WNV is associated with significant morbidity and mortality. The mainstay of treatment is supportive care. Electroencephalography (EEG) allows for identification of nonconvulsive status epilepticus and other epileptiform and nonepileptiform patterns suggestive of underlying cognitive dysfunction. Our aim was to describe specific EEG patterns observed in WNV neuroinvasive disease. Methods: A retrospective chart review was conducted. West Nile virus was confirmed with serum and/or cerebrospinal fluid markers. Patients with a history of abnormal EEG were excluded. Electroencephalography reports were classified into categories based on the presence of epileptiform activity, focal slowing, generalized periodic discharges with triphasic morphology, and frontally predominant generalized rhythmic delta activity. Results: In our cohort of 34 patients, 60% of focal EEG abnormalities were anterior-predominant, seen as epileptiform discharges, focal slowing, or frontally predominant generalized rhythmic delta activity. Nonepileptiform EEG patterns included nonspecific slowing and generalized periodic discharges with triphasic morphology. Two patients had electrographic seizures, one arising from the frontocentral head region. Conclusions: EEGs are important in the evaluation of WNV infection to rule out seizures or alternative causes of encephalopathy, and because of the risk of nonconvulsive seizures or status epilepticus in encephalitis. Although an anterior predominance of EEG abnormalities was seen in our cohort, this most likely is more correlative to encephalopathy than WNV itself. Although a specific correlative EEG pattern may not accompany all cases of WNV neuroinvasive disease, WNV should be considered as a possible etiology in patients presenting with an encephalitic or meningitic syndrome in the presence of abnormal EEG findings including encephalopathic patterns, particularly those with anterior predominant EEG changes.
Outcomes of young patients with Waldenstrom macroglobulinemia (WM).
Vallumsetla, Nishanth, Ansell, Stephen M. , Lacy, Martha Q. , Hayman, Suzanne R. , Kyle, Robert A. , Kumar, Shaji , Kapoor, Prashant , Paludo, Jonas , Gertz, Morie A. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8609-8609

10.1200/jco.2014.32.15_suppl.8609 Get It

Trends in survival of patients with primary plasma cell leukemia: A population-based analysis from 1973 to 2010.
Lacy, Martha Q. , Gupta, Vinay , Kapoor, Prashant , Lust, John A., Hayman, Suzanne R. , Zeldenrust, Steven R., Kyle, Robert A. , Kumar, Shaji , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Go, Ronald S. , Dispenzieri, Angela , Singh, Preet Paul , Buadi, Francis K. , Dingli, David , Lin, Yi , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8608-8608

10.1200/jco.2014.32.15_suppl.8608 Get It